Results 11 to 20 of about 20,104,039 (259)
Chronic Hepatitis C [PDF]
Gut and Liver, 2011 The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment.Jang, Jae Young, Chung, Raymond T.doaj +3 more sourcesChronic Hepatitis C with Cyanosis
Case Reports in Hepatology, 2019 Background. There are multiple aetiologies for dyspnea in patients with liver disease, including pneumonia, pulmonary embolism, hepatic hydrothorax, portopulmonary syndrome, and hepatopulmonary syndrome.Mahmood Alawainati, Jawad Khamis, Muneer Abdulla, Saeed Alsaeed +3 moredoaj +3 more sourcesChronic hepatitis C [PDF]
BMJ, 2007 Hepatitis C infection is a treatable disease.1 Generally, people with chronic hepatitis C are relatively asymptomatic but risk progression over time to cirrhosis and its complications. Combination antiviral therapy with pegylated interferon and ribavirin achieves sustained virological response rates of 42-80% depending on genotype.2 In August 2006 the ...Kosh, Agarwal, Timothy J S, Cross, Charles, Gore +2 moreopenaire +2 more sourcesA genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C [PDF]
, 2012 Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.Jörg Bojunga, Raffaele Malinverni, Gerlach, Tilman J., Gerlach, Tilman J, Tilman J Gerlach, Swiss Hepatitis C Cohort Study Group,, Berg, T., Kutalik, Z., Stephanie Bibert, Christian M Lange, Geier, Andreas, Dufour, Jean-François Jacques, Thomas Berg, Malinverni, Raffaele, Regenass, S., Burgisser, Philippe, Regenass, Stephan, Badenhoop, Klaus, Bojunga, Jörg, Lange, Christian M, Dufour, J. F., Stephan Regenass, Gerlach, Tilman Joern, Swiss Hepatitis C Cohort Study Group, Bochud, P. Y., Dufour, Jean-Francois, Bojunga, J., Andreas Geier, Stefan Zeuzem, Negro, F., Cerny, A., Zoltan Kutalik, Lange, Christian, Pierre-Yves Bochud, Sarrazin, C., Tobias Müller, Sarrazin, Christoph, Lange, C. M., Cerny, Andreas, Kutalik, Zoltán, Bibert, S., Malinverni, R., Moradpour, Darius, Christoph Sarrazin, Burgisser, P., Gerlach, T. J., Moradpour, D., Bibert, Stephanie, Klaus Badenhoop, Zeuzem, S., Negro, Francesco, Müller, Tobias, Badenhoop, K., Andreas Cerny, Bochud, Pierre-Yves, Geier, A., Heim, M. H., Muller, T., Francesco Negro, Berg, Thomas, Markus H Heim, Heim, Markus H., Darius Moradpour, Jean-Francois Dufour, Philippe Burgisser, Heim, Markus H, Zeuzem, Stefan +66 morecore +2 more sourcesManagement of chronic hepatitis C [PDF]
Postgraduate Medical Journal, 2005 AbstractHepatitis C virus (HCV) infection is transmitted primarily through percutaneous exposure to blood, and most infections are associated with injection drug use. Progression to chronic HCV occurs in 55% to 86% of infected people, and persistent infection is a major cause of cirrhosis, end stage liver disease, and hepatocellular carcinoma.V, Lo Re, J R, Kostmanopenaire +2 more sourcesTracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection [PDF]
, 2007 Background. CD4+ T cell help is critical in maintaining antiviral immune responses and such help has been shown to be sustained in acute resolving hepatitis C.Paul Klenerman, GRÜNER N, Thimme, R., J. Tilman Gerlach, Weber, Jonathan N., Ulsenheimer, Axel, Helmut M. Diepolder, PFAFFEROT K, Semmo, N, Scriba, Thomas J, Silvana Gaudieri, Hans Nitschko, Grüner Norbert, SANTANTONIO, TERESA ANTONIA, Haberstroh, Anita, Diepolder Helmut M., Pfafferot, Katja, Jung, Maria-Christina, Rauch, A, Norbert Grüner, Andri Rauch, Scriba, T.J., Obermeier, M., Diepolder, HM, Pape Gerd R., Jonathan N Weber, Gaudieri Silvana, Malte H. J. Heeg, OBERMEIER M, Anita Haberstroh, SCHRAUT W, Jung, M-C, Gerd R Pape, Michaela Lucas, FIDLER S, RAUCH A, DAY C, Phillips, Rodney, Malte H.J. Heeg, Gaudieri, S., Maria-Christina Jung, Thimme Robert, Pape, Gerd R., Obermeier, Martin, Obermeier Martin, Day Cheryl, Obermeier, M, Rodney Phillips, Klenerman Paul, Heeg, MH, Martin Obermeier, Haberstroh, A., Day, C., Klenerman, Paul, Grüner, Norbert, Zachoval, R., Thimme, Robert, Baumert, Thomas F., Phillips, R., Gerlach, JT, Haberstroh Anita, Gerlach, J Tilman, Klenerman, P, Santantonio, T., ZACHOVAL R, Ulsenheimer, A., Nitschko, Hans, Lucas, Michaela, Nasser Semmo, Zachoval Reinhart, KLENERMAN P, Weber, J.N., Baumert Thomas F., Bowyer, S., Fidler, Sarah, Phillips Rodney, Haberstroh, A, Heeg Malte H.J., ULSENHEIMER A, Thomas F. Baumert, Baumert, TF, Diepolder, Helmut M, Axel Ulsenheimer, Thomas F Baumert, Gruener, N, Pfafferot, K, Pape, GR, Helmut M Diepolder, BAUMERT TF, Winfried Schraut, Jung, M.C., Zachoval, R, Gerlach, J.T., Thimme, R, Phillips, R, LUCAS M, Semmo, N., Heeg, Malte H. J., Semmo Nasser, HEEG MH, Gerlach J. Tilman, Nitschko Hans, HABERSTROH A, Santantonio Teresa, Robert Thimme, Grüner, N., Santantonio, T, Schraut Winfried, Klenerman, P., Pape, Gerd R, J. Tilman, Santantonio, Teresa, Scriba, Thomas J., Nitschko, H., Jung, MC, Jonathan N. Weber, Reinhart Zachoval, Scriba, TJ, NITSCHKO H, Lucas, M., Katja Pfafferot, Jung Maria-Christina, Fidler, S., Heeg, M., Schraut, Winfried, Malte H J Heeg, J Tilman Gerlach, Pfafferot Katja, Weber Jonathan N., Diepolder, H.M., Baumert, T.F., Gaudieri, S, Cheryl Day, GAUDIERI S, PAPE GR, Lucas, M, Fidler Sarah, WEBER JN, DIEPOLDER HM, Weber, Jonathan N, Schraut, W., Day, C, Ulsenheimer, A, Gerlach, J. Tilman, SEMMO N, Thomas J Scriba, Ulsenheimer Axel, Day, Cheryl, Lucas Michaela, PHILLIPS R, Diepolder, Helmut M., Pfafferott, K., Heeg, MHJ, Fidler, S, Rauch, A., Thomas J. Scriba, GERLACH JT, Gruner, N, Nitschko, H, Heeg, Malte H J, Gerd R. Pape, Sarah Fidler, Rauch Andri, Rauch, Andri, Baumert, Thomas F, Scriba Thomas J., Pape, G.R., Schraut, W, THIMME R, Semmo, Nasser, Weber, JN, JUNG MC, Teresa Santantonio, Gaudieri, Silvana, Zachoval, Reinhart, SCRIBA TJ +175 morecore +2 more sourcesSoluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity [PDF]
, 2012 Aim: Cellular CD81 is a well characterized hepatitis C virus (HCV) entry factor, while the relevance of soluble exosomal CD81 in HCV pathogenesis is poorly defined.Kronenberger Bernd, Stefan Zeuzem, Reichert, David, Kronenberger, Bernd, Martinez, Yolanda, Martinez Yolanda, Bernd Kronenberger, Susser, Simone, Sarrazin, Christoph, Herrmann Eva, Susser Simone, Zeuzem Stefan, Piiper, Albrecht, Christoph Sarrazin, Simone Susser, Reichert David, Piiper Albrecht, Herrmann, Eva, Sarrazin Christoph, Martin-Walter Welker, Welker Martin-Walter, Albrecht Piiper, Eva Herrmann, Welker, Martin-Walter, David Reichert, Zeuzem, Stefan, Yolanda Martinez +26 morecore +2 more sourcesChronic Hepatitis C in the Pandemic
Klimik Dergisi/Klimik Journal, 2021 Corona virus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, affected all the world and has been a major cause for significant morbidity and mortality. COVID-19 represents with pulmonary manifestations, but in more than half of the cases, other organs, especially hepatic involvement, are observed ...Süda Tekin, Şua Sümer, Neşe Demirtürk, Bilgehan Aygen +3 moreopenaire +3 more sourcesResponse to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]
, 2003 Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.Konig, A., Folwaczny, Christian, Schmidt, F., Simperl, C., Schaefer, M., Torok, P., Glas, J., Schiemann, Uwe, Martin, K. +8 morecore +1 more source
